Vaxcyte, Inc. (PCVX)
PCVX price $63.43 -2.80 -4.23%
- Ticker
- PCVX
- Price
- $63.43
- Change
- -2.80 -4.23%
- Market cap
- $9.98B
- P/E
- -8.67
- Forward P/E
- 85.33
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 67
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease…